Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AGILON HEALTH, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

07/12/2021 | 04:57pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 9, 2021, the Board of Directors (the "Board") of agilon health, inc. (the "Company") approved an increase in size to eleven directors effective as of July 12, 2021, and Karen McLoughlin was elected to the Board as a Class II director in accordance with the Company's amended and restated certificate of incorporation, effective as of July 12, 2021, to fill the vacancy on the Board created by the increase in Board size. Ms. McLoughlin was also elected as a member of the audit committee of the Board. Ms. McLoughlin will hold office until the 2023 annual general meeting of stockholders or until removed from office in accordance with the Company's amended and restated certificate of incorporation. There was no arrangement or understanding between Ms. McLoughlin and any other person pursuant to which she was selected as a director.

Ms. McLoughlin was the Chief Financial Officer of Cognizant Technology Solutions ("Cognizant") from 2012 to 2020. Prior to joining Cognizant in 2003, Ms. McLoughlin was Vice President, Finance at Spherion from 1997 to 2003, Director, Corporate Accounting at Ryder Systems, Inc. from 1994 to 1997, and Manager, Middle Market Group at Price Waterhouse (which is now known as PricewaterhouseCoopers) from 1988 to 1994. Ms. McLoughlin currently serves on the board of directors of Best Buy as a member of the audit committee and chair of the finance and investment policy committee. Ms. McLoughlin received her B.A. from Wellesley College and her MBA from Columbia University.

The Company believes Ms. McLoughlin has the qualifications and skills to serve as a director of the Company due to her experience as an executive at a large public company and her experience as a public company director, as well as her financial and accounting expertise.

Related Party Transactions

There are no related party transactions reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.

Director Compensation

Ms. McLoughlin will be compensated in accordance with previously disclosed compensation programs for the Company's non-officer directors.

Item 8.01 Other Events.

On July 12, 2021, the Company issued a press release announcing the appointment of Ms. McLoughlin as a director, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number                             Description
 99.1       Press Release dated July 12, 2021
  104     Cover Page to this Current Report on Form 8-K in Inline XBRL.


© Edgar Online, source Glimpses

All news about AGILON HEALTH, INC.
09/15INSIDER SELL : Agilon Health
09/10AGILON HEALTH : Cowen Starts agilon health at Outperform with $44 Price Target
09/10AGILON HEALTH : Prices Secondary Share Offering At $30 Per Share
09/09AGILON HEALTH : Announces Pricing of Secondary Offering
09/07AGILON HEALTH : Stockholders to Offer 17 Million Common Shares in Secondary Offe..
09/07AGILON HEALTH : Announces Secondary Offering
09/05AGILON HEALTH : September 2021 Investor Presentation
08/26AGILON HEALTH : to Participate in Upcoming Investor Conferences
08/04AGILON HEALTH : Reports Second Quarter 2021 Results (Form 8-K)
08/04AGILON : Q2 Earnings Snapshot
More news
Analyst Recommendations on AGILON HEALTH, INC.
More recommendations